Surrozen Inc (SRZN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Surrozen Inc (SRZN) has a cash flow conversion efficiency ratio of 0.045x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.49 Million) by net assets ($-278.15 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See SRZN defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Surrozen Inc - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Surrozen Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Surrozen Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Surrozen Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Anhui Huangshan Capsule Co Ltd
SHE:002817
|
0.046x |
|
Liaoning SG Automotive Group Co Ltd
SHG:600303
|
-0.081x |
|
Koramco Energy Plus Reit Co Ltd
KO:357120
|
0.207x |
|
Alliance Entertainment Holding Corporation Class A Common Stock
NASDAQ:AENT
|
0.176x |
|
LAVIPHARM S.A. NA EO 1
F:BXA0
|
N/A |
|
Baiyang Aquatic Group Inc
SHE:002696
|
-0.140x |
|
Kaplamin Ambalaj Sanayi ve Ticaret AS
IS:KAPLM
|
-0.027x |
|
Biostar Microtech International Corp
TW:2399
|
-0.047x |
Annual Cash Flow Conversion Efficiency for Surrozen Inc (2019–2025)
The table below shows the annual cash flow conversion efficiency of Surrozen Inc from 2019 to 2025. For the full company profile with market capitalisation and key ratios, see SRZN market cap.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-187.76 Million | $-30.24 Million | 0.161x | -80.46% |
| 2024-12-31 | $-21.38 Million | $-17.63 Million | 0.825x | +177.49% |
| 2023-12-31 | $37.94 Million | $-40.36 Million | -1.064x | -83.18% |
| 2022-12-31 | $76.00 Million | $-44.15 Million | -0.581x | -30.54% |
| 2021-12-31 | $109.70 Million | $-48.81 Million | -0.445x | +27.68% |
| 2020-12-31 | $47.29 Million | $-29.10 Million | -0.615x | +14.13% |
| 2019-12-31 | $29.39 Million | $-21.06 Million | -0.717x | -- |
About Surrozen Inc
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, … Read more